Biotechnology Technology Transfer Law In Russia.
1. Introduction
Biotechnology technology transfer law in Russia concerns the legal framework governing the development, ownership, licensing, commercialization, export, import and transfer of biotechnology-related inventions, scientific knowledge, research materials and industrial processes between universities, research institutions, biotechnology companies, pharmaceutical manufacturers and foreign organizations.
Technology transfer is particularly important in the following areas:
Genetic engineering and genome editing.
Pharmaceutical and vaccine development.
Stem-cell and regenerative medicine.
Synthetic biology and genetically modified organisms (GMOs).
Industrial biotechnology and bio-manufacturing.
Agricultural biotechnology and plant breeding.
Biopharmaceutical patents and biological production processes.
Laboratory research, biological materials and scientific know-how.
Russia does not regulate biotechnology technology transfer through one comprehensive statute. Instead, several laws operate together, particularly the Civil Code, legislation on genetic engineering, pharmaceutical regulation, intellectual property, scientific research and export controls.
An important legal distinction is that transferring intellectual property does not automatically authorize the recipient to manufacture, test or market a biotechnology product. Patent authorization, regulatory approval, biosafety compliance and export-control permission are separate legal requirements.
2. Principal Legislative Framework
The principal laws governing biotechnology technology transfer in Russia are:
| Legislation | Legal significance |
|---|---|
| Civil Code, Part IV | Patents, licensing, know-how and technology ownership |
| Federal Law No. 86-FZ of 5 July 1996 | Regulation of genetically engineered activities |
| Federal Law No. 127-FZ of 23 August 1996 | Science and state scientific and technical policy |
| Federal Law No. 98-FZ of 29 July 2004 | Protection of commercial secrets and confidential know-how |
| Federal Law No. 217-FZ of 2 August 2009 | Commercialization of research results by budget-funded scientific and educational institutions |
| Federal Law No. 183-FZ of 18 July 1999 | Export control of dual-use technologies |
| Federal Law No. 61-FZ of 12 April 2010 | Circulation of medicines |
| Federal Law No. 180-FZ of 23 June 2016 | Biomedical cell products |
These laws create a framework in which scientific discoveries can be converted into commercial products while protecting intellectual property, public health and national security.
3. Civil Code of Russia: Technology Transfer and Intellectual Property
The most important legislation is Part IV of the Russian Civil Code, particularly Articles 1225–1554.
It recognizes several forms of intellectual property relevant to biotechnology:
Patented inventions and utility models.
Industrial designs.
Computer programs and scientific databases.
Breeding achievements.
Integrated circuit topographies.
Trade secrets and know-how.
A. Article 1225 – Protected intellectual property
Article 1225 identifies the intellectual property categories protected under Russian law.
In biotechnology, these may include:
Novel biological manufacturing processes.
Genetic-engineering techniques.
Pharmaceutical compositions.
Laboratory-developed technologies.
Proprietary biological production methods.
Not every biological discovery or naturally occurring substance automatically qualifies for patent protection. The invention must satisfy the applicable patentability requirements.
B. Articles 1235–1238 – Licensing arrangements
These provisions regulate licensing and sublicensing.
A biotechnology company may grant another company permission to use:
A patented genetic-engineering process.
A vaccine manufacturing technique.
A proprietary laboratory procedure.
A pharmaceutical production technology.
A protected biotechnology database or computer program.
Russian law recognizes two principal forms of licensing:
Exclusive licence: The licensee receives exclusive rights within the contractual scope.
Non-exclusive licence: The patent holder can continue using the technology and grant licences to other parties.
Article 1235 requires a written licence agreement and identification of the intellectual property and permitted methods of use. A paid licence must also specify the remuneration or a method for determining it.
C. Articles 1365–1369 – Patent transfer and licensing
These provisions regulate the transfer of patent ownership and licensing of inventions.
For example, a Russian biotechnology research institute may transfer its patent rights over a recombinant protein production process to a pharmaceutical manufacturer.
Article 1369 is particularly important because patent assignments and licences concerning inventions require compliance with applicable state-registration requirements.
USPTO+1
4. Articles 1542–1554: The Legal Framework for Integrated Technology Transfer
Chapter 77 of Part IV of the Civil Code is especially important.
It establishes the legal framework for the transfer of an integrated technological system.
An integrated technology may combine several intellectual property rights into one commercially usable system.
For example, a biotechnology production system may contain:
A patented genetic modification.
A proprietary fermentation process.
A laboratory-developed production protocol.
Specialized software.
Confidential manufacturing information.
Important provisions:
| Article | Legal principle |
|---|---|
| 1542 | Concept of integrated technology |
| 1544 | Rights of the person organizing technology development |
| 1545 | Obligation to implement the technology |
| 1546 | Rights of the Russian Federation and its constituent entities |
| 1547 | Transfer of state-owned technology rights |
| 1548 | Remuneration for technology transfer |
| 1549 | Joint ownership of technology |
| 1550 | General conditions for transferring technology rights |
| 1551 | Export of integrated technology |
Article 1544: Ownership of developed technology
Generally, the organization responsible for developing integrated technology using budgetary funds obtains the relevant rights, subject to the statutory exceptions.
The organization must take appropriate steps to secure intellectual property rights, including patent applications, registration and protection of confidential information.
Article 1545: Obligation to implement technology
The rights holder is required to ensure the practical implementation of the technology.
This is important because Russian law does not treat publicly funded technological development simply as an intellectual property ownership exercise. Commercial or practical implementation is also a statutory concern.
Article 1546: Government ownership
In specified circumstances, technology developed with federal or regional budget funding belongs to the Russian Federation or the relevant constituent entity.
This can arise where:
The technology directly relates to defence or national security.
The government finances the development necessary to bring it into practical application.
The developer fails to secure the necessary intellectual property rights within the prescribed six-month period.
Article 1549: Joint ownership
Where government funds, private investors and research institutions jointly finance biotechnology research, technology rights may be shared.
The parties should establish ownership, licensing authority, revenue distribution and commercialization responsibilities before beginning the research.
Article 1550: Transfer of technology
This provision permits technology rights to be transferred through assignments, licensing agreements and other contractual arrangements.
Article 1551: Export of integrated technology
This is especially significant for international biotechnology cooperation.
An integrated technology should primarily be implemented in Russia. Its use abroad may require the consent of the state customer or budget-funds administrator, where applicable.
Transactions providing for the use of integrated technology outside Russia are subject to registration with the competent intellectual property authority. Failure to comply with the statutory registration requirement can invalidate the transaction.
wipo.int+2
5. Federal Law No. 86-FZ: Genetic Engineering Technology Transfer
The Federal Law No. 86-FZ of 5 July 1996, on State Regulation in the Field of Genetically Engineered Activities, is an important biotechnology-specific statute.
It addresses the environmental, ecological and human-health dimensions of genetic engineering.
Its relevance includes:
Genetically modified organisms.
Genetic-engineering research.
Recombinant DNA and RNA technologies.
Biological safety.
The handling and application of genetic-engineering technologies.
The amendments introduced by Federal Law No. 643-FZ of 29 December 2022 expanded the statutory treatment of genetic information and genetic data.
A further important development is Federal Law No. 43-FZ of 20 February 2026, which amended the framework to address human genetic data and population genetic and immunological research.
Consequently, biotechnology transfer arrangements involving genetic information must distinguish between transferring a technological invention and transferring genetic data. They raise different legal compliance questions.
For example, a Russian biotechnology company transferring genetic-analysis technology to a foreign research partner must consider:
Ownership and licensing of the underlying technology.
The legal status of the genetic information.
Applicable personal-data and confidentiality requirements.
Export-control restrictions.
Research and biosafety requirements.
CIS Legislation+2
6. Federal Law No. 217-FZ: Commercialization of University and Research-Institute Biotechnology
Federal Law No. 217-FZ of 2 August 2009 is important for transferring research results from publicly funded educational and scientific institutions into commercial markets.
It facilitates the creation of commercial companies by scientific and educational institutions for the practical application of intellectual property created through scientific research.
For example:
A Russian university develops a new genetic-engineering process for producing therapeutic proteins. The university may establish or participate in a commercial company to manufacture and commercialize the technology, subject to the statutory requirements.
The legal issues include:
Ownership of research inventions.
Allocation of intellectual property between researchers and institutions.
Licensing of university-developed patents.
Commercial participation by research institutions.
Distribution of commercialization revenue.
Protection of confidential research information.
Conflicts of interest between academic and commercial activities.
The objective is to bridge the gap between laboratory research and industrial biotechnology.
7. Trade Secrets and Confidential Biotechnology Know-How
Federal Law No. 98-FZ of 29 July 2004, on Commercial Secrets, protects confidential commercial information.
Biotechnology companies frequently possess valuable information that is not necessarily protected by patents.
Examples include:
Fermentation parameters.
Cell-culture conditions.
Protein purification procedures.
Manufacturing protocols.
Genetic-engineering production methods.
Proprietary laboratory datasets.
Industrial-scale biological production techniques.
Article 1465 of the Civil Code also recognizes know-how as an intellectual property category.
Article 1466 establishes the exclusive right to use protected know-how.
Article 1467 addresses the duration of protection, which continues while the relevant confidentiality conditions are maintained.
Practical example:
A Russian biotechnology company transfers a vaccine-manufacturing process to a foreign pharmaceutical manufacturer.
The agreement should specify:
Which technical documents may be disclosed.
Who may access laboratory records.
Whether employees can share production information.
Whether the recipient may develop competing processes.
Whether sublicensing is permitted.
How confidential materials must be returned or destroyed.
A patent protects qualifying inventions through a statutory intellectual property right. Trade-secret protection instead depends on maintaining legally sufficient confidentiality.
8. Export Control and International Biotechnology Technology Transfer
Federal Law No. 183-FZ of 18 July 1999, on Export Control, establishes the framework for controlling foreign economic activities involving potentially sensitive goods, information, services and intellectual property.
This is particularly important for biotechnology because some biological materials and technologies can have both civilian and military applications.
Government Resolution No. 1287 of 16 July 2022 establishes a list of microorganisms, toxins, equipment and technologies subject to export control.
The list includes several categories:
Human-pathogenic microorganisms and toxins.
Animal-pathogenic microorganisms.
Plant-pathogenic microorganisms.
Genetically modified microorganisms and genetic elements.
Specialized equipment.
Controlled technologies.
Relevant software.
CIS Legislation+2
A. Controlled technology transfers
A biotechnology company may require authorization before transferring controlled technical information to a foreign recipient.
Technology transfer is not restricted to physical shipment. It may also involve:
Sending technical manufacturing documents.
Providing specialized technical assistance.
Training foreign personnel.
Transmitting controlled technical data.
Giving a foreign partner access to controlled production knowledge.
B. Import and export of biological materials
Government Resolution No. 572 of 2 April 2022 regulates the import and export of certain pathogenic microorganisms and viruses.
The applicable requirements must be assessed alongside the separate export-control regime under Resolution No. 1287.
Consultant Plus+1
C. Fundamental scientific research exception
An important distinction is that the Resolution No. 1287 list excludes publicly available information, fundamental scientific research and information necessary for preparing a patent application from export control under that list.
However, this does not create a blanket exemption for physical biological materials, commercial technical assistance or other controlled transfers.
9. Pharmaceutical and Biomedical Technology Transfer
Technology transfer involving pharmaceutical biotechnology must comply with additional regulatory requirements.
A. Federal Law No. 61-FZ of 12 April 2010 – Circulation of Medicines
This legislation regulates the circulation of medicines in Russia.
Its relevance includes:
Pharmaceutical manufacturing.
State registration of medicinal products.
Quality and safety requirements.
Pharmaceutical production technologies.
Manufacturing and distribution authorization.
A foreign company may license its patented biopharmaceutical production process to a Russian manufacturer. However, the Russian manufacturer must independently satisfy applicable pharmaceutical regulatory requirements.
B. Federal Law No. 180-FZ of 23 June 2016 – Biomedical Cell Products
This legislation establishes the framework for biomedical cell products.
It is relevant to the transfer of technologies involving:
Cell-based therapeutic products.
Cell cultivation and processing.
Regenerative medicine.
Biomedical cellular manufacturing.
Quality and safety controls.
A technology-transfer agreement cannot replace the required regulatory authorization for the relevant biomedical activity.
C. Clinical research and technology transfer
Where a biotechnology transfer involves clinical research, the parties must also address:
Research ethics.
Clinical-trial authorization.
Patient consent.
Biological sample handling.
Data protection.
Research-result ownership.
Responsibility for adverse events.
10. Important Judicial Decisions and Case Laws
Russia follows a civil-law legal system. Therefore, legislation and authoritative judicial interpretations are especially important. Judicial decisions provide guidance in applying the statutory rules, but individual judgments should not automatically be treated as binding precedents in the common-law sense.
There is a relatively limited body of publicly identifiable judgments specifically concerning the international transfer of biotechnology technology. Nevertheless, pharmaceutical patent and intellectual property disputes provide important guidance.
Case 1. Nativa LLC v. Celgene Corporation (2017–2019)
Important compulsory licensing decision
Case number: A40-71471/2017.
Court: Moscow Arbitration Court, with subsequent appellate proceedings.
Subject: Lenalidomide patent rights.
Relevant provision: Article 1362 of the Civil Code.
Facts:
Celgene held Russian patent rights relating to lenalidomide, a pharmaceutical substance used in cancer treatment.
Nativa sought a compulsory licence to use the patented invention, relying on its own patent concerning a crystalline form of the substance.
Legal issue:
Could a Russian company obtain a compulsory licence to use another company's patented pharmaceutical technology?
Legal significance:
The court granted a compulsory licence, making this an important early example of compulsory licensing in Russian pharmaceutical patent litigation.
However, an important qualification is necessary: Nativa's underlying patent was subsequently invalidated by Rospatent for lack of inventive step, and the parties eventually settled the dispute and the compulsory licence was annulled.
Relevance to biotechnology:
The dispute illustrates that pharmaceutical technology transfer may occur through statutory compulsory licensing rather than voluntary contractual agreement. It also demonstrates the importance of ensuring that the licensee's own patent rights remain valid.
IAM+1
Case 2. Sugen LLC and Pharmacia & Upjohn v. Nativa LLC (2019–2020)
Significant compulsory licensing judgment
Case number: A40-166505/2017.
Important decision: 29 October 2019.
Court: Intellectual Property Rights Court.
Further review: Russian Supreme Court proceedings, 20 February 2020.
Subject: Sunitinib pharmaceutical patent.
Relevant provision: Article 1362 of the Civil Code.
Facts:
Sugen LLC and Pharmacia & Upjohn held patent rights relating to sunitinib, a pharmaceutical substance used in cancer treatment.
Nativa marketed a corresponding medicine and asserted rights under its own patent.
The patent holders brought infringement proceedings. Nativa filed a counterclaim seeking recognition of its invention as dependent and a compulsory licence.
Legal issue:
Whether a patent holder with a dependent invention could obtain a compulsory licence where the statutory requirements were satisfied.
Judicial outcome:
The courts granted the compulsory-licence claim. The Intellectual Property Rights Court upheld the result in its decision of 29 October 2019, and the Supreme Court dismissed a further challenge on 20 February 2020.
Legal significance:
The dispute illustrates the relationship between:
Patent exclusivity.
Dependent inventions.
Significant technical or economic advantages.
Compulsory licensing.
Access to pharmaceutical technology.
Relevance to biotechnology:
The case is particularly useful for understanding licensing disputes involving complex pharmaceutical technologies and biotechnology-derived medicines. It is a pharmaceutical patent case, not a direct genetic-engineering technology-transfer judgment.
iclrc.ru+2
Case 3. Supreme Court of Russia – Resolution No. 10 of 23 April 2019
Authority: Plenary Session of the Supreme Court of the Russian Federation.
Date: 23 April 2019.
Subject: Application of Part IV of the Civil Code.
Relevant provisions: Articles 1225, 1232, 1234 and 1235.
Legal principles:
The Resolution provides authoritative guidance on the interpretation and enforcement of intellectual property rights.
It clarifies important principles concerning:
Ownership of intellectual property.
Exclusive rights and personal non-property rights.
Written agreements for transferring intellectual property.
Licensing and assignment.
State registration where legally required.
Judicial protection against unauthorized use.
Paragraph 37 is particularly relevant to technology-transfer agreements. A contract described as an assignment may be interpreted as a licence if it actually imposes restrictions on the duration, territory or methods of use.
Biotechnology relevance:
A company transferring a patent for a genetic-engineering process must ensure that the agreement accurately reflects whether ownership is being transferred or only permission to use the technology is being granted.
USPTO+1
Case 4. Intellectual Property Court – Pharmaceutical Patent Disputes
The Nativa litigation also demonstrates the importance of patent validity, technical evidence and the relationship between dependent patents.
In biotechnology disputes, similar evidentiary questions may arise concerning:
Novelty of a biological production method.
Inventive step in genetic-engineering processes.
Industrial applicability.
Technical disclosure in patent applications.
Ownership of improvements developed by licensees.
These issues must be determined under the applicable Civil Code provisions and patent examination requirements. The pharmaceutical decisions provide useful analogies, but they do not establish that every biological manufacturing method is patentable.
11. Legal Requirements for Biotechnology Technology-Transfer Agreements
A properly drafted technology-transfer agreement should address the following matters.
| Contractual element | Legal importance |
|---|---|
| Identification of technology | Defines the transferred invention or process |
| Ownership | Establishes the legitimate rights holder |
| Patent licensing | Determines permitted patent use |
| Know-how protection | Protects confidential technical information |
| Territory | Defines geographical limits |
| Duration | Establishes the licence period |
| Royalties | Determines payment obligations |
| Sublicensing | Controls further transfer to third parties |
| Quality control | Protects manufacturing standards |
| Regulatory compliance | Allocates approval responsibilities |
| Export control | Addresses controlled technology transfers |
| Liability | Allocates responsibility for losses |
| Termination | Determines when transfer rights end |
Example:
A Russian biotechnology company enters into an agreement with an Indian pharmaceutical manufacturer to transfer recombinant vaccine manufacturing technology.
The agreement should distinguish between:
Patent rights.
Manufacturing know-how.
Biological materials.
Technical documentation.
Training and technical assistance.
Regulatory responsibilities.
Export authorization.
Rights to subsequent improvements.
The parties should also determine whether the Indian manufacturer can independently manufacture, modify and distribute the resulting product.
12. Government Institutions Responsible for Biotechnology Technology Transfer
Several Russian institutions play important roles in the regulatory system.
| Institution | Principal responsibility |
|---|---|
| Rospatent | Patent registration and intellectual property administration |
| Ministry of Science and Higher Education of Russia | Scientific research and innovation policy |
| Ministry of Industry and Trade of Russia | Industrial and technological development |
| Federal Service for Surveillance in Healthcare (Roszdravnadzor) | Healthcare and medical-product supervision |
| Federal Service for Technical and Export Control (FSTEC) | Export-control administration |
| Ministry of Health of Russia | Pharmaceutical and biomedical policy |
Their responsibilities overlap in certain circumstances. Consequently, biotechnology companies must identify the applicable approval and registration requirements before transferring technology.
13. Major Legal Challenges
Russia's biotechnology technology-transfer system faces several important legal challenges.
A. Public funding and ownership conflicts
Disputes may arise between universities, researchers, investors and government institutions concerning ownership of publicly funded inventions.
B. International technology-transfer restrictions
Export-control requirements can complicate international biotechnology partnerships, especially where controlled microorganisms, genetic elements or technical information are involved.
C. Patent protection and compulsory licensing
Biotechnology companies must balance patent exclusivity with statutory compulsory-licensing mechanisms.
D. Protection of confidential information
The unauthorized disclosure of genetic-engineering processes, manufacturing protocols and laboratory know-how can cause substantial commercial losses.
E. Regulatory approval
A licence to use biotechnology intellectual property does not automatically authorize the manufacture or marketing of medicines, cell products or other regulated biological products.
F. Genetic-data governance
The 2026 amendments to Federal Law No. 86-FZ make the legal treatment of human genetic data particularly important in research partnerships and international biotechnology cooperation.
G. International sanctions and cooperation
Restrictions imposed by foreign jurisdictions can affect cross-border research collaboration, access to scientific equipment, licensing arrangements, financing and technology supply chains. Russian domestic authorization alone does not guarantee that a foreign partner may lawfully participate.
14. Recommendations for Strengthening Russian Biotechnology Technology-Transfer Law
Several improvements could strengthen the Russian legal framework:
Develop clearer ownership rules for jointly funded biotechnology inventions.
Improve transparency in licensing publicly funded research.
Establish clearer procedures for international biotechnology collaboration.
Strengthen contractual protection of genetic data and biological materials.
Improve coordination between patent authorities and biosafety regulators.
Clarify compulsory-licensing standards for pharmaceutical and biotechnology inventions.
Establish more consistent rules for technology-transfer valuation.
Improve protection of university and research-institute intellectual property.
Strengthen compliance procedures for controlled biological technologies.
Encourage responsible commercialization of biotechnology innovations.
15. Conclusion
Biotechnology Technology Transfer Law in Russia is based primarily on the Civil Code, Federal Law No. 86-FZ, Federal Law No. 98-FZ, Federal Law No. 183-FZ and related pharmaceutical and scientific research legislation.
The most significant provisions are Articles 1542–1554 of the Civil Code, which regulate integrated technology ownership, commercialization, joint ownership and international transfer.
The Nativa–Celgene and Sugen–Nativa disputes demonstrate the importance of compulsory licensing and patent enforcement in pharmaceutical technology commercialization. The Supreme Court's Resolution No. 10 of 23 April 2019 provides additional guidance on intellectual property assignments and licensing agreements.
Ultimately, the Russian framework attempts to balance three major objectives:
Innovation: Encouraging scientific discoveries and biotechnology commercialization.
Protection: Safeguarding patents, confidential know-how and research investments.
National interests: Ensuring biosafety, pharmaceutical regulation and control of sensitive technology exports.
The central legal challenge is ensuring that biotechnology research can move from laboratories into commercial production without compromising intellectual property rights, public health or national security.
16. Important Legal Sources and Further Reading
Russian Civil Code, Part IV – Rospatent
Federal Law No. 86-FZ – Genetic Engineering Activities
Federal Law No. 183-FZ – Export Control
Government Resolution No. 1287 of 2022 – Controlled Microorganisms and Technologies
Supreme Court Resolution No. 10 of 23 April 2019
WIPO – Russian Intellectual Property Legislation
Nativa v. Celgene – Compulsory Licensing Analysis
Academic research qualification: The cases discussed above are principally pharmaceutical patent and intellectual property decisions used by analogy. They should not be described as a comprehensive body of biotechnology-specific technology-transfer precedents. For litigation or commercial transactions, the current Russian-language legislation and full court judgments should be checked.

comments